The economic impact of biosimilars on the Australian health care system is now clearer, with data revealing their role in reducing market expenditure and driving price competition.
Researchers conducted the analysis to address a critical challenge facing health care payers: balancing the rapid growth in indications and costs of biologic medicines with finite health budgets. The researchers recognized that once patents for reference products expire, the introduction of biosimilar medicines is a key strategy to provide continued patient access to necessary treatments while ensuring the long-term affordability of funding schemes.
The primary objective of the present study was to describe the specific impact of biosimilars on the volume and cost of biologics within the Australian market. To achieve this, the research team extracted Australian sales data for selected biologic medicines with at least one biosimilar available for a minimum of 12 months. The data, spanning a decade from 2010 to 2020, was sourced from IQVIA-MIDAS. The researchers measured expenditure in US dollars and volume in standardized units (SUs). They calculated the differences in expenditure, volume, and average SU price for both the reference product and the total market for the 12-month periods before and after biosimilar market entry.
A key finding was the substantial reduction in total expenditure for biologic reference products. Just 12 months after a biosimilar entered the market, the expenditure for the reference product was reduced by 38.3%. This occurred in a market that experienced only a minimal increase in overall use, demonstrating that the savings were primarily driven by price reduction rather than a change in market size.
The price competition was also evident in the per-unit cost. The average price of a standardized unit for reference products decreased by 30% to 40%. Furthermore, the study confirmed that the price of biosimilar standardized units was as much as 40% lower than the price of their reference products. By 2020, the cumulative effect of these introductions was clear: biosimilars had grown to account for 30% of the total biologics market in Australia.
The demonstrated cost savings and increased market penetration indicate that biosimilars are not only viable alternatives but are also essential for maintaining accessible and affordable health care.
Reference:
Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Dibutyl sulfide is an organosulfur. It is a clear, colorless to pale yellow liquid characterized by a strong sulfur-like odor and is primarily used as an intermediate in chemical synthesis, specialty organic manufacturing, and research applications. The compound exhibits good solvency properties and moderate thermal stability, making it useful in industrial and laboratory processes involving sulfur-containing organic compounds.
Oleylamine is a long-chain (C18) primary fatty amine derived from natural fatty acids, typically sourced from vegetable oils. It is produced from oleic acid through conversion of the carboxylic acid group (–COOH) into an amine group (–NH₂). With its optimal balance of hydrophobic chain length and reactive amine functionality it serves as a versatile and dependable building block for high-performance formulations.
Sodium Hyaluronate is the sodium salt of hyaluronic acid, a naturally occurring glycosaminoglycan known for its exceptional ability to retain moisture, along with its viscoelastic and biocompatible properties, making it highly valuable across pharmaceutical, cosmetic, and biomedical applications.